<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11742479</article-id><article-id pub-id-type="pmc">2363984</article-id><article-id pub-id-type="pii">6692161</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2161</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase I and pharmacokinetic study of intraperitoneal topotecan</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hofstra</surname><given-names>L S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bos</surname><given-names>A M E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vries</surname><given-names>E G E de</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zee</surname><given-names>A G J van der</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Beijnen</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rosing</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mulder</surname><given-names>N H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Aalders</surname><given-names>J G</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Willemse</surname><given-names>P H B</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medical, <label>2</label>Gynaecologic Oncology, University Hospital Groningen, PO Box 30.001, Groningen, RB, 9700, The Netherlands</aff><aff id="aff3"><label>3</label>Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, Amsterdam, EC, 1066, The Netherlands</aff><pub-date pub-type="ppub"><month>11</month><year>2001</year></pub-date><volume>85</volume><issue>11</issue><fpage>1627</fpage><lpage>1633</lpage><history><date date-type="received"><day>27</day><month>11</month><year>2000</year></date><date date-type="rev-recd"><day>02</day><month>08</month><year>2001</year></date><date date-type="accepted"><day>17</day><month>09</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p><italic>Purpose</italic>: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan. <italic>Patients and methods</italic>: Fifteen patients with recurrent ovarian cancer in a phase I trial were treated with escalating IP topotecan doses (5&#x02013;30&#x02008;mg/m<sup>2</sup>) for pharmacokinetic analysis. <italic>Results</italic>: Dose limiting toxicity (DLT) was acute hypotension, chills and fever at the 30&#x02008;mg/m<sup>2</sup> dose level. Haematological toxicity and abdominal pain were mild for all dose levels studied. <italic>Pharmacokinetics</italic>: Peak plasma levels of total topotecan were reached at 2.7 &#x000b1; 1.1&#x02008;h after IP instillation. The apparent V <sub>ss</sub> was 69.9 &#x000b1; 25.4&#x02008;L/m<sup>2</sup>, plasma clearance 13.4 &#x000b1; 2.5&#x02008;L/h/m<sup>2</sup> and plasma T1/2 3.7 &#x000b1; 1.3&#x02008;h. The plasma AUC was correlated with the dose (R = 0.95, <italic>P</italic> &#x0003c; 0.01). The plasma AUC ratio of lactone versus total topotecan (lactone + carboxy-forms) increased with the dose from 16&#x00025; to 55&#x00025;, (R = 0.84, <italic>P</italic> &#x0003c; 0.01). Peritoneal total topotecan was cleared from the peritoneal cavity at 0.4 &#x000b1; 0.3&#x02008;L/h.m<sup>2</sup> with a T1/2 = 2.7 &#x000b1; 1.7&#x02008;h. The mean peritoneal/plasma AUC ratio for total topotecan was 54 &#x000b1; 34. <italic>Conclusion</italic>: A substantial dose of topotecan can be delivered by the IP route, achieving cytotoxic plasma levels of topotecan, with acceptable toxicity. The recommended dose for further phase II trials is 20&#x02008;mg/m<sup>2</sup> IP, which enables combination with active doses of other cytotoxic drugs, in view of its limited myelotoxicity when given by this route. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>intraperitoneal</kwd><kwd>topotecan</kwd><kwd>ovarian cancer</kwd><kwd>pharmacokinetics</kwd><kwd>phase I</kwd></kwd-group></article-meta></front></article>


